Cancer Immunotherapy Market to Reach a Market Size of $128.3 Billion by 2024 - KBV Research

News provided by

KBV Research

23 Jan, 2019, 14:00 GMT

NEW DELHI, January 23, 2019 /PRNewswire/ --

According to a new report Global Cancer Immunotherapy Market, published by KBV research, The Global Cancer Immunotherapy Market size is expected to reach $128.3 billion by 2024, rising at a market growth of 14.3% CAGR during the forecast period. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

     (Logo: https://mma.prnewswire.com/media/519478/KBV_Research_Logo.jpg )

North America held the largest market share in 2017, followed by Europe. Asia Pacific on the other hand would be the fastest-growing region during the analysis period. The leading factors that drive the growth of Asia Pacific market are growing patient population suffering from various kinds of cancers, growing prevalence of different types of cancer, governmental contribution towards R&D activities and healthcare reforms for the treatment of cancer.

Access Full Report: https://www.kbvresearch.com/cancer-immunotherapy-market/

The Monoclonal Antibodies market dominated the Global Cancer Immunotherapy Market by Technology 2017, thereby, achieving a market value of $61,048.9 million by 2024. The Cytokines & Immunomodulators market is expected to witness a CAGR of 12.8% during (2018 - 2024). Additionally, The Other Technology market is expected to witness highest CAGR of 15.2% during (2018 - 2024).

The Lung Cancer market dominated the Global Cancer Immunotherapy Market by Application 2017, growing at a CAGR of 13 % during the forecast period. The growth is attributed to the growing prevalence of this type of cancer and demand for advanced treatment options. The Melanoma market is expected to witness a CAGR of 16% during (2018 - 2024). Additionally, The Head & Neck Cancer market is expected to witness highest CAGR of 14.9% during (2018 - 2024).

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd.

Global Cancer Immunotherapy Market Segmentation  

By Technology 

  • Monoclonal Antibodies,
  • Cytokines & Immunomodulators
  • Other technology

By Application  

  •  Lung cancer
  •  Breast cancer
  • Colorectal
  •  Prostate cancer
  • Head & Neck cancer
  • Other application.

By End User 

  • Hospitals
  • Clinics
  • Other End User

By Geography 

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled 

  • AstraZeneca
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer Ag
  • Immunomedics Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd

Unique Offerings from KBV Research 

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

About Us: 

Knowledge Based Value Research is a global brand and consulting firm serving all kinds of business verticals, government and non-governmental organizations, and not-for-profit organizations. Our motto is to extend our services that will have a lasting impact on our clients who trust us with their business goals.

Our aim is to transform and customize our services to address the fast changing business needs of our clients. With innovative methods, we seek to empower our research tools with new capabilities that would eventually bring about customer delight, as we understand that businesses evolve.

Media Contact:
Mr. Alan D'Souza
KBV Research
244 Fifth Avenue, Suite 1407
New York, N.Y. 10001
United States (U.S)
Tel: +1(646)661-6066
Email: query@kbvresearch.com